Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by PMV Pharmaceuticals, Inc. on June 5, 2025. The meeting was conducted exclusively via live webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance voting outcomes.
Material Changes and Voting Results
Proposal 1: Election of Directors
Stockholders elected two Class II Directors to serve until the 2028 annual meeting:
- Arnold Levine, Ph.D.: Approved with 26,723,192 votes FOR, 5,118,916 WITHHELD, and 8,760,485 BROKER NON-VOTES.
- Charles M. Baum, M.D., Ph.D.: Approved with 13,258,337 votes FOR, 18,583,771 WITHHELD, and 8,760,485 BROKER NON-VOTES.
Proposal 2: Executive Compensation (Say-on-Pay)
The non-binding advisory vote to approve the compensation of Named Executive Officers was not approved by stockholders.
- FOR: 11,646,401
- AGAINST: 20,170,398
- ABSTAIN: 25,309
- BROKER NON-VOTE: 8,760,485
The Company conducts annual advisory votes on executive compensation, a policy expected to continue until the 2028 annual meeting.
Proposal 3: Ratification of Auditors
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- FOR: 39,963,653
- AGAINST: 638,940
- ABSTAIN: 0
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial performance, or new risk factors. The rejection of the executive compensation proposal represents a significant governance event that may influence future management decisions, though no specific remedial actions were detailed in this report.
Investor Verification Checklist
- Review the definitive Proxy Statement (Schedule 14A) filed on April 25, 2025, for details on the executive compensation package that was rejected.
- Monitor subsequent press releases or filings for the Board's response to the failed Say-on-Pay vote.
- Verify the tenure and background of the newly elected directors, Arnold Levine and Charles M. Baum.
- Confirm the engagement terms with Ernst & Young LLP for the 2025 fiscal year.